about
Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activityCyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosisArylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.Synthesis, characterization and biological activity of ring-substituted 6-benzylamino-9-tetrahydropyran-2-yl and 9-tetrahydrofuran-2-ylpurine derivatives.The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, (57)Fe Mössbauer), theoretical, and biological activity studies.Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors.Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action.Cyclin-dependent kinase inhibitors as anticancer drugs.Novel potent pharmacological cyclin-dependent kinase inhibitors.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Biological Evaluation of Dipyrromethanes in Cancer Cell Lines: Antiproliferative and Pro-apoptotic Properties.ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.Substituted 2-hydroxy-N-(arylalkyl)benzamide sensitizes cancer cells to metabolic stress by disrupting actin cytoskeleton and inhibiting autophagic flux.Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.Discovery of nitroaryl urea derivatives with antiproliferative properties.Novel arylazopyrazole inhibitors of cyclin-dependent kinases.Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes.Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines.Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance.A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.Synthesis and biological evaluation of guanidino analogues of roscovitine.Cdk2 inhibition prolongs G1 phase progression in mouse embryonic stem cells.Antifungal activity of silver nanoparticles against Candida spp.Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.Preparation, biological activity and endogenous occurrence of N6-benzyladenosines.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.Tumour suppressor PTEN regulates cell cycle and protein kinase B/Akt pathway in breast cancer cells.Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.8-Azapurines as new inhibitors of cyclin-dependent kinases.Preparation, physicochemical properties and biological activity of copper(II) complexes with 6-(2-chlorobenzylamino)purine (HL1) or 6-(3-chlorobenzylamino)purine (HL2). The single-crystal X-ray structure of.
P50
Q27667021-61D46AC0-AF92-469A-9475-5454CD3F136FQ28732702-723101C0-5C50-44EB-B0C5-608FA648CF31Q31160552-C86E0B80-A842-41BD-9F93-5A1389CBE8C1Q33411115-0EED9EC9-7EFC-45D7-819C-734FD56C2222Q33522499-31900A39-C2EB-4731-A07B-D7A11E405AB7Q34555921-8D16B9CB-8D2A-4AED-B6E2-EA2B6F9071E0Q35106892-00801D99-2D8E-4F41-B81B-03843885ACDEQ35621163-D5617CE6-76F8-4D9B-86CB-BF0F3B922636Q35850522-2C639920-5003-4B6C-B4B2-EFA6819C98BAQ37704502-C490B681-344F-46BB-9C97-1C13CEA019E7Q37855812-ACAB7442-0C61-4BF2-9869-2D14CFD1BEACQ38008733-28481E82-8B1E-4F31-812D-386BEF061723Q38538589-973D9E05-6F79-45CB-99FA-3859FA8F2E2AQ38544813-2E3F8B3C-E2BB-4C0F-9B2F-1753F2AF11FBQ38708843-AF29D040-FAC9-4495-A7D0-50E55E56CF96Q38718833-CAEF8CB3-290A-4B3D-828F-61DB110689D5Q38740468-BC133365-A4B9-4C4C-B01E-99B6365EFA17Q38793642-1F65227E-7AC6-4B8B-AAC4-610FF1ACAFDFQ38796012-1AE3A970-F173-4246-B590-13E8496ED1C4Q38805892-F145CB81-9BE6-4FE1-B7D2-8A105B4D22E1Q38850709-63BA05F2-098E-4603-A54C-7D8453298EBEQ38859827-4F4F6F80-8E46-4463-8F49-EB72DD52F886Q38891661-FE85FACC-E515-42EA-8683-9153A5940AA1Q38907321-D2EFA04D-8504-45A9-985C-096168512F11Q38995743-3D712F30-199B-4651-AB31-C510F18365CCQ39104360-6AAFF80B-BFB6-477F-9F62-6A1751FC7288Q39111186-00CBEFF4-1060-4904-88B1-951B49477348Q39129932-C57D332E-7FBE-4E0F-A776-DDD3C0FF67F5Q39196489-3F0229BF-35FD-455D-BED3-5DB135C96531Q39802361-D7991419-DBE0-4722-8470-3CD4D802E818Q39809782-A1BE82B2-AC54-417B-867F-32DBD8E0DAD8Q39930544-AA951BD6-B49A-454B-BB2D-BC47959631DAQ40147923-5A05C58D-15E8-4B4A-A102-5B0D236B8C2EQ40216003-78F11429-36C7-4C63-80AA-D82517E59246Q40291233-9DCD482D-9AE7-4F5C-BD0F-3A75B24FB6A1Q40334959-E07F7C9D-8847-4BDF-8682-2125E62BA805Q40363853-9AB0DF69-6419-4716-B993-141E9B7D74BDQ40400301-45D7912B-DA70-493A-9BA2-88F69F601F8AQ40402939-31231645-3583-498A-BF9A-7A108B421019Q40809202-48993BFB-969D-4ADE-8263-C5DBC65E306F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Vladimír Krystof
@ast
Vladimír Krystof
@sl
Vladimír Kryštof
@cs
Vladimír Kryštof
@en
Vladimír Kryštof
@es
type
label
Vladimír Krystof
@ast
Vladimír Krystof
@sl
Vladimír Kryštof
@cs
Vladimír Kryštof
@en
Vladimír Kryštof
@es
altLabel
Vladimir Krystof
@en
prefLabel
Vladimír Krystof
@ast
Vladimír Krystof
@sl
Vladimír Kryštof
@cs
Vladimír Kryštof
@en
Vladimír Kryštof
@es
P214
P1053
B-9499-2009
P106
P1153
7004713828
P19
P21
P214
P31
P3829
P496
0000-0001-5838-2118
P569
1973-08-04T00:00:00Z
P691
P735
P7859
viaf-90614086